The question as to whether inhibition of both enzymes would provide synergistic benefits for cancer patients, remains very much an open question and has fuelled recent efforts into the development of dual IDO1/TDO2 inhibitors [34,35] or TDO2-selective inhibitors [36] that could be used in conjunction with IDO1-selective inhibitors. Here, IDO1 is linked to cancer.